Tenpoint Therapeutics™ is a clinical stage biopharmaceutical company launching a new era in presbyopia treatment and developing an innovative pipeline targeting the largest areas of unmet need for rejuvenating vision in the aging eye.

Events

April 4, 2025
RBC Capital Markets Virtual Ophthalmology Conference: Webcast

April 8, 2025
24th Annual Needham Virtual Healthcare Conference: Webcast

Press Releases

April 8, 2025

Tenpoint Therapeutics Ltd. Submits New Drug Application to U.S. FDA for BRIMOCHOL PF for the Treatment of Presbyopia

Tenpoint Therapeutics Ltd. Submits New Drug Application to U.S. FDA for BRIMOCHOL PF for the Treatment of Presbyopia

March 31, 2025

Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in April

Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in April

March 11, 2025

Tenpoint Therapeutics Ltd. Appoints Carol Kearney as Chief Commercial Officer

Tenpoint Therapeutics Ltd. Appoints Carol Kearney as Chief Commercial Officer

January 9, 2025

Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Pivotal Study, BRIO-II, of BRIMOCHOLTM PF for the Treatment of Presbyopia

Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Pivotal Study, BRIO-II, of BRIMOCHOLTM PF for the Treatment of Presbyopia

NEWS

March 11, 2025

With AbbVie in its sights, Tenpoint names commercial chief ahead of vision drug launch

January 9, 2025

10s for Tenpoint: Biotech preps for '26 market launch after phase 3 win for combo eye drop

November 1, 2022

What to Know About New Topical Presbyopia-Correcting Drops